HSTOQ — Histogen Share News
0.000.00%
Last trade - 00:00FinancialsHighly SpeculativeMicro Cap
- $0.01m
- -$5.60m
- $3.77m
Histogen Inc reports results for the quarter ended in September - Earnings Summary
Brief: Histogen Reports Qtrly Loss Per Share Of 9 Cents
Histogen Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Histogen Announces CEO Transition
Brief: Histogen And Amerimmune Announce Presentation Of Emricasan Data In COVID-19 At The American College Of Allergy, Asthma, And Immunology Conference
Brief: Histogen Inc - Received Letter From Nasdaq Indicating Co Did Not Meet Minimum Bid Price Of $1 Per Share Required For Continued Listing
Brief: Histogen And Amerimmune Announce Additional Findings From Its Phase 1 Study Of Emricasan In Mild Symptomatic Covid-19 Patients
Histogen Inc reports results for the quarter ended in June - Earnings Summary
Brief: Histogen Posts Quarterly Loss Per Share Of $0.10
Histogen Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Histogen Announces Initiation Of Hst 003 Phase 1/2 Trial For Knee Cartilage Regeneration
Histogen jumps on positive results from early-stage COVID-19 drug trial
Brief: Histogen And Amerimmune Announce Positive Top-Line Study Results From Its Phase 1 Study Of Emricasan In Mild Symptomatic Covid-19 Patients
Brief: Histogen Announces Closing Of $6.5 Mln Registered Direct Offering
Brief: Histogen Reports $6.5 Mln Registered Direct Offering
Brief: Histogen Inc Says Top-Line Data For Phase 1 Study Of Emricasan In Mild-Symptomatic Covid-19 Patients Anticipated In June 2021
Histogen Inc reports results for the quarter ended in March - Earnings Summary
Brief: Histogen Reports Qtrly Loss Per Share $0.14
Histogen Inc expected to post a loss of 15 cents a share - Earnings Preview